BMJ Open Respiratory Research (Dec 2023)

CT airway remodelling and chronic cough

  • Jean Bourbeau,
  • Emiel F M Wouters,
  • Wan Tan,
  • Miranda Kirby,
  • Robab Breyer-Kohansal,
  • Sylvia Hartl,
  • Marie-Kathrin Breyer,
  • Otto C Burghuber,
  • Hazim Abozid,
  • Neha Nasir

DOI
https://doi.org/10.1136/bmjresp-2022-001462
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

Rationale Structural airway changes related to chronic cough (CC) are described in the literature, but so far reported data are rare and non-conclusive. Furthermore, they derive mainly from cohorts with small sample sizes. Advanced CT imaging not only allows airway abnormalities to be quantified, but also to count the number of visible airways. The current study evaluates these airway abnormalities in CC and assesses the contribution of CC in addition to CT findings on the progression of airflow limitation, defined as a decline in forced expiratory volume in 1 s (FEV1) over time.Methods A total of 1183 males and females aged ≥40 years with thoracic CT scans and valid spirometry from Canadian Obstructive Lung Disease, a Canadian multicentre, population-based study has been included in this analysis. Participants were stratified into 286 never-smokers, 297 ever-smokers with normal lung function and 600 with chronic obstructive pulmonary disease (COPD) of different severity grades. Imaging parameters analyses included total airway count (TAC), airway wall thickness, emphysema as well as parameters for functional small airway disease quantification.Results Irrespective of COPD presence, CC was not related to specific airway and lung structure features. Independent of TAC and emphysema score, CC was highly associated with FEV1 decline over time in the entire study population, particularly in ever-smokers (p<0.0001).Conclusion The absence of specific structural CT features independently from COPD presence indicate that other underlying mechanisms are contributing to the symptomatology of CC. On top of derived CT parameters, CC seems to be independently associated with FEV1 decline.Trial registration number NCT00920348.